Scott Ferrara, DO
Pulmonary Disease · Lodi, NJNPI 1710305339
Payments from drug & device makers
Across 684 payments — averaging $70.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$36K
- GSK$3K
- Pulmonx Corporation$2K
- Intuitive Surgical$1K
- Amgen$773
- Boehringer Ingelheim$713
- plus $5K from 28 others
What the payments were for
- Consulting fees$6711%
- Speaking & faculty fees$29,47261%
- Travel & lodging$1,7184%
- Food & beverage$15,12632%
- Education$9832%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 102 | $35,506 |
| GSK | 188 | $2,539 |
| Pulmonx Corporation | 13 | $1,831 |
| Intuitive Surgical | 7 | $1,339 |
| Amgen | 42 | $773 |
| Boehringer Ingelheim | 48 | $713 |
| Sanofi | 34 | $650 |
| Insmed, Inc. | 39 | $593 |
| Mylan Specialty L.p. | 32 | $544 |
| Grifols USA, LLC | 22 | $371 |
| Inspire Medical Systems, Inc. | 9 | $334 |
| Actelion Pharmaceuticals US, Inc. | 16 | $325 |
| Philips North America LLC | 18 | $296 |
| Regeneron Healthcare Solutions, Inc. | 16 | $277 |
| Verona Pharma, Inc. | 16 | $240 |
| Sanofi-aventis U.S. LLC | 3 | $233 |
| Mallinckrodt Hospital Products Inc. | 9 | $231 |
| Viatris Specialty LLC | 10 | $207 |
| Novartis | 11 | $188 |
| ANI Pharmaceuticals, Inc. | 8 | $126 |
| United Therapeutics Corporation | 6 | $95 |
| Merck | 6 | $93 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $91 |
| Bayer | 6 | $83 |
| Harmony Biosciences LLC | 4 | $66 |
| Teva Pharmaceuticals USA, Inc. | 3 | $42 |
| ADMA Biomanufacturing LLC | 2 | $36 |
| Baxter Healthcare | 1 | $30 |
| Pfizer | 2 | $28 |
| Lilly USA, LLC | 1 | $22 |
| Genentech USA, Inc. | 1 | $18 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Tactile Systems Technology Inc | 1 | $16 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FASENRA$32,965
- BREZTRI$1,643
- ZEPHYR ENDOBRONCHIAL VALVE$1,563
- TEZSPIRE$1,259
- Da Vinci Surgical System$1,221
- CHARTIS CATHETER$1,123
- ZEPHYR DELIVERY CATHETER$1,123
- PULMONX CHARTIS TABLET CONSOLE$1,123
- AIRSUPRA$510
- TRELEGY ELLIPTA$372
- FARXIGA$309
- NUCALA$249
- SYMBICORT$231
- Inspire$161
- ANDEXXA$125
- DUPIXENT$123
- PULMICORT RESPULES$121
How this compares
$47,969 in reported general payments places this provider in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 22 | $280,602 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 323 | $231,420 |
| TezspireTezepelumab-Ekko | 22 | $89,347 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 110 | $81,171 |
| Dupixent PenDupilumab | 20 | $73,526 |
| Breo ElliptaFluticasone/Vilanterol | 57 | $45,379 |
| Spiriva RespimatTiotropium Bromide | 31 | $15,822 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 28 | $14,611 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 83 | $11,764 |
| EliquisApixaban | 17 | $11,058 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $6,489 |
| Incruse ElliptaUmeclidinium Bromide | 15 | $6,096 |
| SymbicortBudesonide/Formoterol Fumarate | 19 | $5,643 |
| Advair HfaFluticasone Propion/Salmeterol | 17 | $4,488 |
| Arnuity ElliptaFluticasone Furoate | 13 | $3,488 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta | $2,539 | $300,994436 claims |
| Boehringer IngelheimOfev, Spiriva Respimat | $713 | $296,42453 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Symbicort | $35,506 | $176,161151 claims |
| PfizerEliquis | $28 | $11,05817 claims |
| Teva Pharmaceuticals USA, Inc.Albuterol Sulfate | $42 | $1,95822 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 472 pulmonary disease providers in New Jersey.
Other pulmonary disease in Lodi
- Reynold PanettieriNew Brunswick$2.5M
- Vinay SikandToms River$1.8M
- Stanley FielMorristown$1.3M
- Joseph HoffmanPark Ridge$1.1M
- Robert SussmanSummit$645K
- Ronaldo GoHackensack$563K
- Deborah GossHackensack$558K
- Sabina HussainNew Brunswick$555K
- Manuel CunananMillville$489K
- Emanuele SantomauroHackensack$420K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.